{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpce.simplecast.com%2Fepisodes%2Fa-look-at-eua-outpatient-therapies-8J6a8Fpd","width":444,"version":"1.0","type":"rich","title":"A Look at EUA Outpatient Therapies","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/947d3b7f-3890-4e80-8529-6486b02916d4/c3fab5a8-38a0-4b53-9d8d-5c6c953dd94b/covid-podcast-a-look-at-eua-outpatient-therapies-episode4.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/6e650ad6-9d27-41a5-8c08-df8e20f495fd\" height=\"200\" width=\"100%\" title=\"A Look at EUA Outpatient Therapies\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this fourth episode of the 6-part series, an expert explains what COVID-19 treatments are available in the outpatient setting. The focus is on monoclonal antibodies, bamlanivimab + etesevimab and casirivimab + imdevimab. For both drug combinations, he discusses the Emergency Use Authorization (EUA) indications, evidence on efficacy, and potential toxicities. Claim your credit at pce.is/COV19."}